NCT00226200View on ClinicalTrials.gov

Soluble CD23 Expression in Asthma Patients Treated With OMA

NATerminatedINTERVENTIONAL

Enrollment

80

Participants

Timeline

Start Date

November 30, 2004

Primary Completion Date

October 31, 2007

Study Completion Date

October 31, 2007

Conditions

Asthma

Interventions

DRUG

Omalizumab

Trial Locations (1)

39216

University of Mississippi Medical Center, Jackson

Sponsors

Collaborators (1)

Novartis Pharmaceuticals

All Listed Sponsors

collaborator

Novartis Pharmaceuticals

INDUSTRY

lead

University of Mississippi Medical Center

OTHER